ArticleJournal of clinical medicine research2009
Effect of escitalopram on white blood cells in patients with major depression.
Article in Journal of clinical medicine research, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 8 citations in OpenAlex.
- Efficacy and safety of escitalopram in treatment of severe depression in Chinese population.Metabolic brain disease · 2017Trial
- Investigation of the immunological effects of escitalopram oxalate in the breast cancer co-culture model.Asian biomedicine : research, reviews and news · 2024Article
- Anti-Inflammatory Action of Antidepressants: Investigating the Longitudinal Effect of Antidepressants on White Blood Cell Count.Complex psychiatry · 2023Article
- Drug repurposing of selective serotonin reuptake inhibitors: Could these drugs help fight COVID-19 and save lives?Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundImmunological dysfunctions in the course of depression are recently intensively investigated. Pharmacotherapy of depression is speculated to affect immune response. In this study, our objective was to investigate whether escitalopram treatment would affect white blood cells in patients with major depression.
methodsFifteen patients (11 women and 4 men), meeting the criteria for a current episode of major depressive disorder, were participated. White blood cell (WBC), neutrophil (NEUT), lymphocyte (LYMPH), monocyte (MONO), eosinophyl (EO), and basophyl (BASO) levels were measured at the entry to the study. After 8 weeks of open-label treatment with the selective serotonin reuptake inhibitor escitalopram (10-20 mg/d), the patients were readmitted and the measurements were repeated.
resultsAt the end of the study, LYMPH was found to be significantly decreased compared to the baseline value after 8 weeks treatment with escitalopram (p < 0.001). There was not a significant change in WBC, NEUT, MONO, EO, and BASO parameters.
conclusionsThe present study has shown that escitalopram increased LYMPH in patients with major depression according to these results, the possible treatment of depression with escitalopram must be carried out with caution, in patients with immunological disturbances. KEYWORDS: Escitalopram; Major depression; White blood cells.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.